Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Botulism Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Botulism Overview | 8 | 1 |
| Pipeline Products for Botulism Comparative Analysis | 9 | 1 |
| Botulism Therapeutics under Development by Companies | 10 | 1 |
| Botulism Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Botulism Pipeline Products Glance | 12 | 2 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Botulism Products under Development by Companies | 14 | 1 |
| Botulism Products under Investigation by Universities/Institutes | 15 | 1 |
| Botulism Companies Involved in Therapeutics Development | 16 | 7 |
| CytoDel, LLC | 16 | 1 |
| Hawaii Biotech, Inc. | 17 | 1 |
| Microbiotix, Inc. | 18 | 1 |
| Molecular Targeting Technologies, Inc. | 19 | 1 |
| Nanotherapeutics, Inc. | 20 | 1 |
| Planet Biotechnology Inc. | 21 | 1 |
| XOMA Corporation | 22 | 1 |
| Botulism Therapeutics Assessment | 23 | 9 |
| Assessment by Monotherapy Products | 23 | 1 |
| Assessment by Target | 24 | 2 |
| Assessment by Mechanism of Action | 26 | 2 |
| Assessment by Route of Administration | 28 | 2 |
| Assessment by Molecule Type | 30 | 2 |
| Drug Profiles | 32 | 17 |
| BoNT/A HcR4 Drug Profile | 32 | 1 |
| botulinum vaccine Drug Profile | 33 | 1 |
| botulism [serotype C] vaccine Drug Profile | 34 | 1 |
| botulism [serotypes A, B, C, D, E] vaccine Drug Profile | 35 | 1 |
| botulism [serotypes A, B] vaccine Drug Profile | 36 | 1 |
| Ctyo-111 Drug Profile | 37 | 1 |
| Monoclonal Antibody to Inhibit Botulinum Toxin for Botulism Drug Profile | 38 | 1 |
| OSX-400 Drug Profile | 39 | 1 |
| OSX-400 Backups Drug Profile | 40 | 1 |
| Polyclonal Antibody for Botulism Drug Profile | 41 | 1 |
| Recombinant Peptides to Inhibit Botulinum Toxin for Botulism Drug Profile | 42 | 2 |
| Small Molecules for Botulism Drug Profile | 44 | 1 |
| Small Molecules to Inhibit BoNT/A LC for Botulism Drug Profile | 45 | 1 |
| Small Molecules to Inhibit Botulinum Neurotoxin Type A for Botulism Drug Profile | 46 | 1 |
| XOMA-3-BB Drug Profile | 47 | 1 |
| XOMA-3AB Drug Profile | 48 | 1 |
| Botulism Dormant Projects | 49 | 1 |
| Botulism Discontinued Products | 50 | 1 |
| Botulism Product Development Milestones | 51 | 1 |
| Featured News &Press Releases | 51 | 1 |
| May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing | 51 | 1 |
| Appendix | 52 | 2 |
| Methodology | 52 | 1 |
| Coverage | 52 | 1 |
| Secondary Research | 52 | 1 |
| Primary Research | 52 | 1 |
| Expert Panel Validation | 52 | 1 |
| Contact Us | 52 | 1 |
| Disclaimer | 53 | 1 |